Navigation Links
NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Date:4/14/2009

acture of vaccine specific to the pandemic strain.

Dr. Gale Smith, Vice President of Vaccine Development at Novavax, said, "The discovery that a VLP-based influenza vaccine candidate created through cell-based recombinant technology has the potential to protect against diverse strains of influenza has significant implications for both pre-pandemic and pandemic preparedness. A broadly protective vaccine administered prior to and during the first wave of a pandemic could prevent widespread morbidity and mortality from a newly emerged pandemic influenza strain and allow time for the development of strain-specific vaccines."

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary VLP technology. The company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. The Company has VLP vaccine candidates against seasonal influenza and potential pandemic influenza strains in phase II clinical development.

This report describes the second of two preclinical studies of Novavax's investigational H5N1 pandemic influenza vaccine announced this year that have shown different approaches to achieving broad protection against diverse influenza strains. As announced in February, a VLP vaccine with an HA based on several H5 strains showed broad cross-protection against different H5 strains. In the current study, an alternative route of administration resulted in cross-protection against different HA types. Novavax has shown in clinical trials that an H5N1 VLP candidate vaccine given by intramuscular injection is well tolerated and immunogenic in humans. Preclinical research on alternative pandemic influenza VLP vaccine approaches is expected to continue.

Additional information about Novavax is available at

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
2. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
3. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
5. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
6. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
7. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
8. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
9. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
10. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
11. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Orexigen ... it has received the Day 180 List of Outstanding ... Medicinal Products for Human Use (CHMP) for the NB32 ... / bupropion SR) is an investigational drug candidate being ... of the earlier Day 120 time point were adequately ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... Oct. 1 Maven Biotechnologies today announced that the ... Institute for Allergy and Infectious Disease (NIAID), part of ... TM imaging technology for label-free protein microarrays and ... Maven through the federal stimulus package initiative for Biomedical ...
... The Culex quinquefasciatus mosquito poses a significant ... elephantiasis-causing worms and encephalitis-inducing viruses. An international team of ... the SIB Swiss Institute of Bioinformatics sequenced its genome ... published in today,s issue of Science, describe results from ...
... 1 Vet-Stem, Inc. announced that Dr. Robert Harman, ... entitled "Stem Cell Therapy: Mechanisms of Action" at the ... Surgeons (ACVS) in Seattle, WA, October 21, 2010.   ... http://www.newscom.com/cgi-bin/prnh/20060425/VETSTEMLOGO ) Dr. Harman has presented ...
Cached Biology Technology:Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics 2Major disease-vector mosquito reveals the secrets of its immune system 2Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2
(Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
(Date:7/30/2014)... associate professor Andrew S. Mount, performed cutting-edge research on ... novel anti-fouling paint for ships and boats and also ... team,s findings, published in Nature Communications ... attaches to a wide variety of surfaces using highly ... underwater heavy-duty adhesive. , "In previous research, we were ...
(Date:7/30/2014)... pests, shrinking ranges and a changing climate threaten ... important plants, and so conservationists establish seed collections ... gardens in hopes of preserving some genetic diversity., ... by simple models that offer a one-size-fits-all approach ... recommending saving 50 seed samples regardless of species, ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Saving seeds the right way can save the world's plants 2
... researchers are part of a nationwide team preparing to open ... genome of the single living sister species to all other ... a large shrub found only on the South Pacific island ... diversified over time and provide insight into the key processes ...
... The Ohio State University and Ohio Supercomputer Center ... develop a computer tool that researchers, government leaders and ... in energy-related technology, policy and pricing. Researchers will ... for Energy Pricing and Policy (ICS-EPP), which models the ...
... PHILADELPHIA The American Association for Cancer Research congratulates 12 ... Medicine. They are among the 65 new members and five ... the fields of health and medicine, the award recognizes individuals ... in the fields of health and medicine. "This ...
Cached Biology News:UF to help sequence genome of flowering plants' ancient living relative 2UF to help sequence genome of flowering plants' ancient living relative 3NSF grant to study national energy policy and technology impacts 2The AACR congratulates its members elected to the Institute of Medicine 2
... is designed to knockout or alter genes on ... one week. Red/ET recombination allows the exchange of ... and faithful manner. An FRT-flanked kanamycin resistance marker ... be used to replace a gene on the ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in cell ... Purity: ≥98% by TLC. Soluble in DMSO ... of a 10 mM stock in DMSO is recommended. ... H 2 O with rapid mixing (e.g. 10 μl ...
... to Protein A and, until recently, no readily ... IgM purification. Standard methods for IgM purification generally ... effective for removing all of the major impurities ... Pierce has developed an easy-to-use affinity matrix ...
Biology Products: